Skip to content

Structure-guided identification and functional evaluation of small-molecule candidates predicted to target the LAG-3/MHC-II interface.

Oct 2026 · Bioorganic chemistry (Print) · Vol 184, pp. 110676 · 0 citations · 48 references
Medicine

TL;DR

In the MC38 syngeneic tumor model, both Z21 and Z28, when used in combination with anti-PD-1, reduced tumor growth, accompanied by increased frequency of tumor-infiltrating CD8+ T cells, and the in vitro and in vivo results support Z21 and Z28 as prioritized small-molecule candidates for further investigations.

Abstract

Small-molecule modulators may complement antibody therapy, offering potential advantages such as optimizable chemical structures, improved tumor accessibility, and better flexibility in pharmacokinetic control. Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint receptor that suppresses T-cell function by interacting with MHC-II molecules; however, systematic research on small-molecule modulators targeting LAG-3 remains lacking. In this study, a multi-stage structure-guided screening process was employed to identify candidate compounds targeting a predicted binding pocket adjacent to the LAG-3/MHC-II interface. Starting with approximately 3.9 million compounds database, the study employed a sequential screening and prioritization process involving AutoDock-GPU docking, Glide hierarchical docking, physicochemical and ADMET screening, 500 ns molecular dynamics simulations, and MM/PBSA binding free energy analysis. Based on predicted binding conformations, interface stability, estimated binding energies, and drug-like properties, ligand160490 and ligand223516, hereafter termed Z21 and Z28, were ultimately prioritized for functional evaluation. In activated human peripheral blood mononuclear cells, Z28 increased the frequency of CD4+IFN-γ+ and CD8+IFN-γ+ T cells, whereas Z21 did not exhibit a similar effect. In the MC38 syngeneic tumor model, both Z21 and Z28, when used in combination with anti-PD-1, reduced tumor growth, accompanied by increased frequency of tumor-infiltrating CD8+ T cells. Together, the in vitro and in vivo results support Z21 and Z28 as prioritized small-molecule candidates for further investigations. Subsequent studies should focus on determining whether Z21 and Z28 exert their biological effects by directly binding to LAG-3 and interfering with LAG-3/MHC-II interaction. Our findings support further mechanistic and pharmacological evaluation of Z21 and Z28.

View source

Similar papers

Open access Oct 2026

Structure-guided Discovery of a Computationally Prioritized Candidate for MMP-13 Inhibition with Favorable Drug-likeness

Overall, this integrated computational workflow prioritized cmd6 as a lead candidate with a comparatively balanced docking profile across the evaluated MMP isoforms, supporting its progression to experimental validation.

Doono Mariya, Deepthy Varghese, Titto Varughese et al. · 0 citations
Open access Nov 2026

Structure-based discovery of novel BCL-XL inhibitors through molecular docking and key interaction-guided virtual screening.

BCL-XL, an anti-apoptotic member of the BCL-2 protein family, is an attractive therapeutic target for overcoming apoptosis resistance in cancer. However, the large, shallow, and predominantly hydrophobic nature of its BH3-binding groove has complicated the discovery of potent, drug-like small-molecule inhibitors. Here,...

Hyunjin Kim, Ahyoung Jang, Sung-Woo Hong et al. · 0 citations
Open access Nov 2026

Discovery of novel small-molecule binders targeting IL-6 receptor conformational ensembles to regulate IL-6 signaling.

INTRODUCTION Interleukin-6 (IL-6) signaling via its receptor (IL-6R) is a central driver of inflammation and immune-related diseases. Although monoclonal antibodies targeting this pathway are clinically effective, their limitations, including high costs and parenteral administration, create an urgent need for orally av...

Jing-Yi Yang, Bei-Bei Fu, Qing-Qing Du et al. · 0 citations
Open access 2026

Structure-based design and computational screening of Fyn kinase inhibitors targeting neurodegenerative pathways in Alzheimer's disease

Fyn kinase, a non-receptor tyrosine kinase, plays a crucial role in various cellular processes and is implicated in diseases like neurodegenerative disorders and cancer. The present study employed a structure-based virtual screening approach utilising a pharmacophore model derived from the known inhibitor staurosporine...

Ankit Ganeshpurkar, Dileep Kumar, Qadir Alam et al. · 0 citations
Oct 2026

Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds.

Structural, conformational, energetic, and pharmacokinetic characterization of dutasteride, danazol, and azelastine as candidate CDK6-binding scaffolds are provided.

Syarifuddin Husain, Ruzianisra Mohamed, Khairul Bariyyah Abd. Halim et al. · 0 citations
Open access Nov 2026

Computational Identification and Prioritization of Novel Tankyrase 1 and 2 Inhibitor Candidates Through Structure-Based Design, ADMET Profiling, and Long-Timescale Molecular Dynamics

Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes and is frequently associated with aberrant activation of the Wnt/β-catenin signaling pathway. Because tankyrase 1 and 2 (TNKS1/2) promote Wnt pathway activation through the regulation of AXIN stability, these enzymes represen...

Oscar Saurith-Coronell, Olimpo Sierra-Hernandez, Carlos Vargas-Echeverría et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.